Pouchitis and Pouch Dysfunction

Gastroenterology Clinics of North America

Volumn 38, Issue 4, 2009, Pages 651-668

  Wu, Hao ^a   Shen, Bo ^b  

^a FUDAN UNIVERSITY   (China)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Classification; Complications; Ileal pouch; Inflammatory bowel disease; Pouchitis; Restorative proctocolectomy

Indexed keywords

ALICAFORSEN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AST 120; BISMUTH; BUDESONIDE; CALGRANULIN; CARBOMER; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; DOXYCYCLINE; GLUTAMINE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LACTOFERRIN; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; SHORT CHAIN FATTY ACID; TETRACYCLINE; TINIDAZOLE;

BIOLOGICAL THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CLOSTRIDIUM; CYTOMEGALOVIRUS; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FECES ANALYSIS; FUNGUS; HISTOPATHOLOGY; HUMAN; ILEITIS; ILEOANAL ANASTOMOSIS; INTESTINE ENDOSCOPY; INTESTINE INFECTION; LABORATORY DIAGNOSIS; LEUKAPHERESIS; LOW DRUG DOSE; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; PATHOGENESIS; PROPHYLAXIS; REVIEW; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

COLITIS, ULCERATIVE; HUMANS; INCIDENCE; POUCHITIS; PREVALENCE; PROCTOCOLECTOMY, RESTORATIVE; RISK FACTORS;

EID: 70350776817     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2009.07.002     Document Type: Review

References (130)

1. Dhillon S., Loftus Jr. E.V., Tremaine W.J., et al. The natural history of surgery for ulcerative colitis in a population-based cohort from Olmsted County, Minnesota [abstract]. Am J Gastroenterol 100 (2005) A819
2. Sandborn W.J. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 107 (1994) 1856-1860
3. Winther K.V., Jess T., Langholz E., et al. Survival and cause-specific mortality in ulcerative colitis - follow-up of a population-based cohort in Copenhagen County. Gastroenterology 125 (2003) 1576-1582
4. Tulchinsky H., Hawley P.R., and Nicholls J. Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg 238 (2003) 229-234
5. Belliveau P., Trudel J., Vasilevsky C.A., et al. Ileoanal anastomosis with reservoirs: complications and long-term results. Can J Surg 42 (1999) 345-352
6. Hueting W.E., Buskens E., van der Tweel I., et al. Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients. Dig Surg 22 (2005) 69-79
7. Sagap I., Remzi F.H., Hammel J.P., et al. Factors associated with failure in managing pelvic sepsis after ileal pouch-anal anastomosis (IPAA) - a multivariate analysis. Surgery 140 (2006) 691-703 [discussion: 703-4]
8. Prudhomme M., Dehni N., Dozois R.R., et al. Causes and outcomes of pouch excision after restorative proctocolectomy. Br J Surg 93 (2006) 82-86
9. Nicholls R.J. Review article: ulcerative colitis-surgical indications and treatment. Aliment Pharmacol Ther 16 (2002) 25-28
10. Shen B., Fazio V.W., Lashner B.A., et al. Comprehensive evaluation of inflammatory and non-inflammatory sequelae of ileal pouch-anal anastomosis. Am J Gastroenterol 100 (2005) 93-101
11. Penna C., Dozois R., Tremaine W., et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 38 (1996) 234-239
12. Fazio V.W., Ziv Y., Church J.M., et al. Ileal pouch-anal anastomosis complications and function in 1005 patients. Ann Surg 222 (1995) 120-127
13. Ferrante M., Declerck S., De Hertogh G., et al. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis 14 (2008) 20-28
14. Fleshner P., Ippoliti A., Dubinsky M., et al. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 6 (2008) 561-568
15. Stocchi L., and Pemberton J.H. Pouch and pouchitis. Gastroenterol Clin North Am 30 (2001) 223-241
16. Gionchetti P., Rizzello F., Helwig U., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind placebo controlled trial. Gastroenterology 124 (2003) 1202-1209
17. Abdelrazeq A.S., Kandiyil N., Botterill I.D., et al. Predictors for acute and chronic pouchitis following restorative proctocolectomy for ulcerative colitis. Colorectal Dis 10 (2008) 805-813
18. Penna C., Tiret E., Kartheuser A., et al. Function of ileal J pouch-anal anastomosis in patients with familial adenomatous polyposis. Br J Surg 80 (1993) 765-767
19. Tjandra J.J., Fazio V.W., Church J.M., et al. Similar functional results after restorative proctocolectomy in patients with familial adenomatous polyposis and mucosal ulcerative colitis. Am J Surg 165 (1993) 322-325
20. Shen B., Jiang Z.-D., Fazio V.W., et al. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 6 (2008) 782-788
21. Munoz-Juarez M., Pemberton J.H., Sandborn W.J., et al. Misdiagnosis of specific cytomegalovirus infection of ileoanal pouch as a refractory idiopathic chronic pouchitis. Report of two cases. Dis Colon Rectum 42 (1999) 117-120
22. Mooka D., Furth E.E., MacDermott R.P., et al. Pouchitis associated with primary cytomegalovirus infection. Am J Gastroenterol 93 (1998) 264-266
23. Kühbacher T., Ott S.J., Helwig U., et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 55 (2006) 833-841
24. Ohge H., Furne J.K., Springfield J., et al. Association between fecal hydrogen sulfide production and pouchitis. Dis Colon Rectum 48 (2005) 469-475
25. Gosselink M.P., Schouten W.R., van Lieshout L.M., et al. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis Colon Rectum 47 (2004) 1519-1525
26. Falk A., Olsson C., Ahrne S., et al. Ileal pelvic pouch microbiota from two former ulcerative colitis patients, analysed by DNA-based methods, were unstable over time and showed the presence of Clostridium perfringens. Scand J Gastroenterol 42 (2007) 973-985
27. Komanduri S., Gillevet P.M., Sikaroodi M., et al. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin Gastroenterol Hepatol 5 (2007) 352-360
28. Kroesen A.J., Leistenschneider P., Lehmann K., et al. Increased bacterial permeation in long-lasting ileoanal pouches. Inflamm Bowel Dis 12 (2006) 736-744
29. DeSilva H.J., Jones M., Prince C., et al. Lymphocyte and macrophage subpopulations in pelvic ileal reservoirs. Gut 32 (1991) 1160-1165
30. Hirata I., Berrebi G., Austin L.L., et al. Immunohistological characterization of intraepithelial and lamina propria lymphocytes in control ileum and colon and inflammatory bowel disease. Dig Dis Sci 31 (1986) 593-603
31. Stallmach A., Schafer F., Hoffman S., et al. Increased state of activation of CD4 positive T cells and elevated interferon gamma production in pouchitis. Gut 43 (1998) 499-505
32. Thomas P.D., Forbes A., Nicholls R.J., et al. Altered expression of the lymphocyte activation markers CD30 and CD27 in patients with pouchitis. Scand J Gastroenterol 36 (2001) 258-264
33. Goldberg P.A., Herbst F., Beckett C.G., et al. Leukocyte typing, cytokine expression and epithelial turnover in the ileal pouch in patients with ulcerative colitis and familial adenomatous polyposis. Gut 38 (1996) 549-553
34. Kroesen A.J., Dullat S., Schulzke J.D., et al. Permanently increased mucosal permeability in patients with backwash ileitis after ileoanal pouch for ulcerative colitis. Scand J Gastroenterol 43 (2008) 704-711
35. Akira S., and Takeda A. Toll like receptors signalling. Nat Rev Immunol 4 7 (2004) 499-511
36. Cario E., and Podolsky D.K. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 68 12 (2000) 7010-7017
37. Toiyama T., Araki T., Yoshiyama S., et al. The expression patterns of toll-like receptors in the ileal pouch mucosa of postoperative ulcerative colitis patients. Surg Today 36 (2006) 287-290
38. Heuschen G., Leowardi C., Hinz U., et al. Differential expression of toll-like receptor 3 and 5 in ileal pouch mucosa of ulcerative colitis patients. Int J Colorectal Dis 22 (2007) 293-301
39. Lammers K.M., Ouburg S., Morre S.A., et al. Combined carriership of TLR9 -1237C and CD14 -260T alleles enhances the risk for developing chronic relapsing pouchitis. World J Gastroenterol 11 (2005) 7323-7329
40. Ayabe T., Satchell D.P., Wilson C.L., et al. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol 1 (2000) 113-118
41. Salzman N.H., Ghosh D., Huttner K.M., et al. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature 422 (2003) 522-526
42. Ouellette A., and Bevins C.L. Paneth cell defensins and innate immunity of the small bowel. Inflamm Bowel Dis 7 (2001) 43-50
43. Porter E.M., Bevins C.L., Ghosh D., et al. The multifaceted Paneth cell. Cell Mol Life Sci 59 (2002) 156-170
44. Ghosh D., Porter E.M., Shen B., et al. Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol 3 (2002) 583-590
45. Porter E., van Dam E., Valore E., et al. Broad spectrum antimicrobial activity of human intestinal defensin 5. Infect Immun 65 (1997) 2396-2401
46. Wehkamp J., Salzman N.H., Porter E., et al. Decreased Paneth cell defensins and antimicrobial activity in ileal Crohn's disease. Proc Natl Acad Sci U S A 102 (2005) 18129-18134
47. Kiehne K., Brunke G., Wegner F., et al. Defensin expression in chronic pouchitis in patients with ulcerative colitis or familial adenomatous polyposis coli. World J Gastroenterol 12 (2006) 1056-1062
48. Hirata N., Oshitani N., Kamata N., et al. Proliferation of immature plasma cells in pouchitis mucosa in patients with ulcerative colitis. Inflamm Bowel Dis 14 (2008) 1084-1090
49. Patel R.T., Bain I., Youngs D., et al. Cytokine production in pouchitis is similar to that in ulcerative colitis. Dis Colon Rectum 38 (1995) 831-837
50. Schmidt C., Giese T., Ludwig B., et al. Increased cytokine transcripts in pouchitis reflect the degree of inflammation but not the underlying entity. Int J Colorectal Dis 21 (2006) 419-426
51. Gionchetti P., Campieri M., Belluzzi A., et al. Mucosal concentrations of interleukin-1β, interleukin-6, interleukin-8, and tumor necrosis factor-α in pelvic ileal pouches. Dig Dis Sci 39 (1994) 1525-1531
52. Bulois P., Tremaine W.J., Maunoury V., et al. Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10. Inflamm Bowel Dis 6 (2000) 157-164
53. Patel R.T., Pall A.A., Adu D., et al. Circulating soluble adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol 7 (1995) 1037-1041
54. Chaussade S., Denizot Y., Valleur P., et al. Presence of PAF-acether in stool of patients with pouch ileoanal anastomosis and pouchitis. Gastroenterology 100 (1991) 1509-1514
55. Gertner D.J., Rampton D.S., Madden M.V., et al. Increased leukotriene B4 release from ileal pouch mucosa in ulcerative colitis compared with familial adenomatous polyposis. Gut 35 (1994) 1429-1432
56. Romano M., Cuomo A., Tuccillo C., et al. Vascular endothelial growth factor and cyclooxygenase-2 are overexpressed in ileal pouch-anal anastomosis. Dis Colon Rectum 50 (2007) 650-659
57. Stucchi A.F., Shebani K.O., Leeman S.E., et al. A neurokinin 1 receptor antagonist reduces an ongoing ileal pouch inflammation and the response to a subsequent inflammatory stimulus. Am J Physiol Gastrointest Liver Physiol 285 (2003) G1259-G1267
58. Stallmach A., Chan C.C., Ecker K.-W., et al. Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut 47 (2000) 415-422
59. Ulisse S., Gionchetti P., Alo S., et al. Expression of cytokine, inducible nitric oxide synthase, matrix metalloproteinases in pouchitis: effects of probiotic therapy. Am J Gastroenterol 96 (2001) 2691-2696
60. Leal R.F., Coy C.S., Ayrizono M.L., et al. Differential expression of pro-inflammatory cytokines and a pro-apoptotic protein in pelvic ileal pouches for ulcerative colitis and familial adenomatous polyposis. Tech Coloproctol 12 (2008) 33-38
61. Thomas P.D., Forbes A., Nicholls R.J., et al. Increased mucosal IFN-γ production in pouchitis despite normal functional responses of isolated CD4 cells [abstract]. Gut 44 Suppl 4 (1999) 32A
62. Shepherd N.A., Healey C.J., Warren B.F., et al. Distribution of mucosal morphology and an assessment of colonic phenotype change in the pelvic ileal reservoir. Gut 34 (1993) 101-105
63. Biancone L., Palmieri G., Lombardi A., et al. Tropomyosin expression in the ileal pouch: a relationship with the development of pouchitis in ulcerative colitis. Am J Gastroenterol 98 (2003) 2719-2726
64. Coffey J.C., Rowan F., Burke J., et al. Pathogenesis of and unifying hypothesis for idiopathic pouchitis. Am J Gastroenterol 104 (2009) 1013-1023
65. De Preter V., Bulteel V., Suenaert P., et al. Pouchitis, similar to active ulcerative colitis, is associated with impaired butyrate oxidation by intestinal mucosa. Inflamm Bowel Dis 15 (2009) 335-340
66. Tysk C., Riedesel H., Lindberg E., et al. Colonic glycoproteins in monozygote twins with inflammatory bowel disease. Gastroenterology 100 (1991) 1509-1514
67. Merrett M.N., Soper N., Mortensen N., et al. Intestinal permeability in the ileal pouch. Gut 39 (1996) 226-230
68. Carter K., Di Giovine F.S., Cox A., et al. The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. Gastroenterology 121 (2001) 805-811
69. Meier C., Hegazi R.A., Aisenberg J., et al. Innate immune receptor genetic polymorphisms in pouchitis: is NOD2/CARD15 a susceptibility factor?. Inflamm Bowel Dis 11 (2005) 965-971
70. Schmidt C.M., Lazenby A.J., Hendrickson R.J., et al. Pre-operative terminal ileal and colonic resection histopathology predicts risk of pouchitis in patients after ileoanal pull-through procedure. Ann Surg 227 (1998) 654-662
71. Achkar J.P., Al-Haddad M., Lashner B., et al. Differentiating risk factors for acute and chronic pouchitis. Clin Gastroenterol Hepatol 3 (2005) 60-66
72. Okon A., Dubinsky M., Vasilauskas E.A., et al. Elevated platelet count before ileal pouch-anal anastomosis for ulcerative colitis is associated with the development of chronic pouchitis. Am Surg 71 (2005) 821-826
73. Hata K., Watanabe T., Shinozaki M., et al. Patients with extraintestinal manifestations have a higher risk of developing pouchitis in ulcerative colitis - multivariate analysis. Scand J Gastroenterol 38 (2003) 1055-1058
74. Lepistö A., Kärkkäinen P., and Järvinen H.J. Prevalence of primary sclerosing cholangitis in ulcerative colitis patients undergoing proctocolectomy and ileal pouch-anal anastomosis. Inflamm Bowel Dis 14 (2008) 775-779
75. Shen B., Fazio V.W., Remzi F.H., et al. Risk factors for diseases of ileal pouch-anal anastomosis in patients with ulcerative colitis. Clin Gastroenterol Hepatol 4 (2006) 81-89
76. Fleshner P.R., Vasiliauskas E.A., Kam L.Y., et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 49 (2001) 671-677
77. Kuisma J., Jarvinen H., Kahri A., et al. Factors associated with disease activity of pouchitis after surgery for ulcerative colitis. Scand J Gastroenterol 39 (2004) 544-548
78. Hoda K.M., Collins J.F., Knigge K.L., et al. Predictors of pouchitis after ileal pouch-anal anastomosis: a retrospective review. Dis Colon Rectum 51 (2008) 554-560
79. Fleshner P., Ippoliti A., Dubinsky M., et al. A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 5 (2007) 952-958
80. Boyko E.J., Koepsell T.D., Perera D.R., et al. Risk of ulcerative colitis among former and current cigarette smokers. N Engl J Med 316 (1987) 707-710
81. Shen B., Remzi F.H., Bennett A.E., et al. Association between immune-associated disorders and adverse outcomes of ileal pouch-anal anastomosis. Am J Gastroenterol 104 (2009) 655-664
82. Mathis K.L., Dozois E.J., Larson D.W., et al. Ileal pouch-anal anastomosis and liver transplantation for ulcerative colitis complicated by primary sclerosing cholangitis. Br J Surg 95 (2008) 882-886
83. Cho C.S., Dayton M.T., Thompson J.S., et al. Proctocolectomy-ileal pouch-anal anastomosis for ulcerative colitis after liver transplantation for primary sclerosing cholangitis: a multi-institutional analysis. J Gastrointest Surg 12 (2008) 1221-1226
84. Zins B.J., Sandborn W.J., Penna C.R., et al. Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis. Am J Gastroenterol 90 (1995) 2177-2180
85. Freeman K., Shao Z., Remzi F.H., et al. Orthotopic liver transplantation for primary sclerosing cholangitis in patients with ulcerative colitis: impact on occurrence of chronic pouchitis. Clin Gastroenterol Hepatol 6 (2008) 62-68
86. Shen B., Achkar J.-P., Lashner B.A., et al. Endoscopic and histologic evaluations together with symptom assessment are required to diagnose pouchitis. Gastroenterology 121 (2001) 261-267
87. Moskowitz R.L., Shepherd N.A., and Nicholls R.J. An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir. Int J Colorectal Dis 1 (1986) 167-174
88. Sandborn W.J., Tremaine W.J., Batts K.P., et al. Pouchitis after ileal pouch-anal anastomosis: a pouchitis disease activity index. Mayo Clin Proc 69 (1994) 409-415
89. Shen B., Fazio V.W., Bennett A.E., et al. Effect of withdrawal of non-steroidal anti-inflammatory drug use in patients with the ileal pouch. Dig Dis Sci 52 (2007) 3321-3328
90. Parsi M.A., Shen B., Achkar J.P., et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 126 (2004) 1280-1286
91. Lim M., Gonsalves S., Thekkinkattil D., et al. The assessment of a rapid noninvasive immunochromatographic assay test for fecal lactoferrin in patients with suspected inflammation of the ileal pouch. Dis Colon Rectum 51 (2008) 96-99
92. Parsi M.A., Ellis J.J., and Lashner B.A. Cost-effectiveness of quantitative fecal lactoferrin assay for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. J Clin Gastroenterol 42 (2008) 799-805
93. Johnson M.W., Maestranzi S., Duffy A.M., et al. Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur J Gastroenterol Hepatol 20 (2008) 174-179
94. Johnson M.W., Maestranzi S., Duffy A.M., et al. Faecal M2-pyruvate kinase: a novel, noninvasive marker of ileal pouch inflammation. Eur J Gastroenterol Hepatol 21 (2009) 544-560
95. Schmidt C., Häuser W., Giese T., et al. Irritable pouch syndrome is associated with depressiveness and can be differentiated from pouchitis by quantification of mucosal levels of proinflammatory gene transcripts. Inflamm Bowel Dis 13 (2007) 1502-1508
96. Panis Y., Poupard B., Nemeth J., et al. Ileal pouch-anal anastomosis for Crohn's disease. Lancet 347 (1996) 854-857
97. Shen B., Achkar J.-P., Lashner B.A., et al. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol 97 (2002) 972-977
98. Shen B., Liu W., Remzi F.H., et al. Enterochromaffin cell hyperplasia in irritable pouch syndrome. Am J Gastroenterol 103 (2008) 2293-2300
99. Lohmuller J.L., Pemberton H.J., Dozois R.R., et al. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg 211 (1990) 622-629
100. Mowschenson P.M., Critchlow J.F., and Peppercorn M.A. Ileoanal pouch operation: long-term outcome with or without diverting ileostomy. Arch Surg 135 (2000) 463-465
101. Hurst R.D., Chung T.P., Rubin M., et al. Implications of acute pouchitis on the long-term functional results after restorative proctocolectomy. Inflamm Bowel Dis 4 (1998) 280-284
102. Madiba T.E., and Bartolo D.C. Pouchitis following restorative proctocolectomy for ulcerative colitis: incidence and therapeutic outcome. J R Coll Surg Edinb 46 (2001) 334-337
103. Sandborn W.J. Pouchitis: risk factors, frequency, natural history, classification and public health prospective. In: McLeod R.S., Martin F., Sutherland L.R., et al. (Eds). Trends in inflammatory bowel disease 1996 (1997), Kluwer Academic Publishers, Lancaster (UK) 51-63
104. Shen B. Diagnosis and management of patients with pouchitis. Drugs 65 (2003) 453-461
105. Croagh C., Shepherd S.J., Berryman M., et al. Pilot study on the effect of reducing dietary FODMAP intake on bowel function in patients without a colon. Inflamm Bowel Dis 13 (2007) 1522-1528
106. Stahlberg D., Gullberg K., Liljeqvist L., et al. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum 39 (1996) 1012-1018
107. Elahi B., Nikfar S., Derakhshani S., et al. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci 53 (2008) 1278-1284
108. Gosselink M.P., Schouten W.R., van Lieshout L.M.C., et al. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 47 (2004) 876-884
109. Gionchetti P., Rizzello F., Venturi A., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (2000) 305-309
110. Mimura T., Rizzello F., Helwig U., et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53 (2004) 108-114
111. Pronio A., Montesani C., Butteroni C., et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis 14 (2008) 662-668
112. Gionchetti P., Rizzello F., Morselli C., et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 50 (2007) 2075-2082 [discussion: 2082-4]
113. Shen B., Brzezinski A., Fazio V.W., et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis - experience in clinical practice. Aliment Pharmacol Ther 22 (2005) 721-728
114. McLaughlin S.D., Johnson M.W., Clark S.K., et al. VSL#3 for chronic pouchitis; experience in UK clinical practice [abstract]. Gastroenterology 134 Suppl 1 (2008) A711
115. Madden M.V., McIntyre A.S., and Nicholls R.J. Double-blinded crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 39 (1994) 1193-1196
116. Shen B., Achkar J.P., Lashner B.A., et al. A randomized trial of ciprofloxacin and metronidazole in treating acute pouchitis. Inflamm Bowel Dis 7 (2001) 301-305
117. Isaacs K.L., Sandler R.S., Abreu M., et al., Crohn's and Colitis Foundation of America Clinical Alliance. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 13 (2007) 1250-1255
118. McLaughlin S.D., Clark S.K., Bell A.J., et al. An open study of antibiotics for the treatment of pre-pouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis. Aliment Pharmacol Ther (2008 Oct 3) [Epub ahead print]
119. Araki Y., Mitsuyama K., Nagae T., et al. Leukocytapheresis for the treatment of active pouchitis: a pilot study. J Gastroenterol 43 (2008) 571-575
120. Shen B., Pardi D.S., Bennett A.E., et al. The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis. Am J Gastroenterol 104 (2009) 1468-1740
121. Shen B., Remzi F.H., Lopez A.R., et al. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis [abstract]. BMC Gastroenterol 8 (2008) 26
122. Schaus B.J., Fazio V.W., Remzi F.H., et al. Large polyps in the ileal pouch in patients with underlying ulcerative colitis. Dis Colon Rectum 50 (2007) 832-838
123. Gionchetti P., Rizzello F., Venturi A., et al. Antibiotic combination therapy in patients with chronic treatment-resistant pouchitis. Aliment Pharmacol Ther 13 (1999) 713-718
124. Abdelrazeq A.S., Kelly S.M., Lund J.N., et al. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis 7 (2005) 182-186
125. Mimura T., Rizzello R., Helwig U., et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 16 (2002) 909-917
126. Shen B., Fazio V.W., Remzi F.H., et al. Combined ciprofloxacin and tinidazole in the treatment of chronic refractory pouchitis. Dis Colon Rectum 50 (2007) 498-508
127. Viscido A., Kohn A., Papi C., et al. Management of refractory fistulizing pouchitis with infliximab. Eur Rev Med Pharmacol Sci 8 (2004) 239-246
128. Gionchetti P., Rizzello F., Poggioli G., et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther 25 (2007) 1231-1236
129. Calabrese C., Gionchetti P., Rizzello F., et al. Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. Aliment Pharmacol Ther 27 (2008) 759-764
130. Tulchinsky H., Dotan I., Alper A., et al. Comprehensive pouch clinic concept for follow-up of patients after ileal pouch anal anastomosis: report of 3 years' experience in a tertiary referral center. Inflamm Bowel Dis 14 (2008) 1125-1132